#GLP-1 class

Coverage of the GLP-1 receptor agonist family and its successors.

SLIM LIVER found improved liver-fat and blood-marker results with semaglutide in people with HIV, but the trial had no control group.

A 28-week Japanese cohort found high persistence and modest metabolic change with low-dose tirzepatide in selected older adults.

Seven randomized trials suggest GLP-1 drugs, including semaglutide, can reduce antipsychotic-associated metabolic harm.

A planned semaglutide study will track addiction and social outcomes in 1,200 people, but it has no participant results or public protocol yet.

A 2026 GLP-1 hair loss review links shedding mainly to weight change, but the narrative evidence cannot prove direct drug causation.

A 23-study systematic review found procedure-specific, mostly observational associations rather than a clear benefit or harm in spine surgery.

A 2026 review maps early semaglutide, exenatide, alcohol and tobacco findings without establishing incretin drugs as addiction treatments.

A 2026 meta-analysis found GLP-1 therapy reduced intake by about 271 kcal at one test lunch, with real-world diet effects still uncertain.

A 2026 computational study compared four GLP-1 receptor complexes, finding persistent structural differences without testing clinical outcomes.

A 70-person observational study linked four months of oral semaglutide care with lower weight, mostly through reduced fat mass.

A 2026 pediatric obesity drug review links adolescent semaglutide evidence with adult retatrutide research while leaving long-term safety open.

A 2026 review finds short-term benefits from adolescent GLP-1 therapy but major gaps around growth, puberty, cognition and lifelong effects.